PMU12 Cost-Benefit Analysis of Sodium Glucose Cotransporter-2 Inhibitor Use for Patients 65 Years with Type 2 Diabetes and Heart Failure with Reduced Ejection Fraction
Jun 1, 2021, 00:00 AM
10.1016/j.jval.2021.04.724
https://www.valueinhealthjournal.com/article/S1098-3015(21)00941-4/fulltext
Section Title :
Section Order :
10235
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)00941-4&doi=10.1016/j.jval.2021.04.724